Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib plus amivantamab subcutaneous versus intravenous in EGFR-mutated advanced or metastatic non-small cell lung cancer after osimertinib and platinum chemotherapy
MOH_2022-08-15_011935Phase 3Completed
- Sponsor
- GC Care
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC), sponsored by GC Care. Primary endpoint: Amivantamab blood exposure comparability. Started Jul 2022; status: completed.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-08-15_011935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-15_011935.